
Can Stem Cells Help With Chemotherapy-Induced Peripheral Neuropathy?
9 min readMSC and exosome research for chemotherapy-induced neuropathy shows promise in mice, but no human treatment is validated. Here is what evidence and ASCO guidance say.
An independent reference library on stem cell therapy and cancer immunotherapy research.
471 articles · 2 topics · 351 Stem Cell Research · 120 Cancer Immunotherapy
Step 1 — Topic
Step 2 — Category
All 471 articles

MSC and exosome research for chemotherapy-induced neuropathy shows promise in mice, but no human treatment is validated. Here is what evidence and ASCO guidance say.

South Korea’s GLP-1 drug boom and unapproved research-peptide clinic market are different stories. What MFDS enforcement and the human evidence actually show.

Autoimmune cell therapies range from specialist-endorsed AHSCT in aggressive MS to early CAR-T lupus trials and investigational MSCs for arthritis and IBD.

Weight management, strength training and injury prevention have the strongest evidence for protecting joints; diet has more limited support and cannot reverse cartilage loss.

Type 1 diabetes is an autoimmune loss of insulin-producing cells. Learn standard insulin and glucose-monitoring care and where investigational stem-cell-derived islets stand.

Hematopoietic stem cells make blood and immune cells throughout life. Where they live, how transplants work, and why they differ from MSCs.

FDA registration is an administrative filing, not proof a stem cell therapy works. How to check claims, trial status, consent and oversight.

Your own stem cells avoid donor rejection, but not surgical, processing or injection risks. Published harm reports and FDA guidance explain why.

SITC's 41st Annual Meeting runs November 4–8, 2026 in Phoenix. Confirmed details, expected themes, registration and ways to follow the event.

In a 38-person Phase 1 myeloma study, anito-cel produced a 100% response rate and no delayed neurotoxicity. What larger trials and FDA review must still establish.

Crohn’s stem cell research: why the ADMIRE-CD II trial reversed early promise for perianal fistulas, and why HSCT for luminal disease remains high-risk.

Japan’s safety-first regenerative medicine rules allow commercial anti-aging MSC clinics without proof of efficacy. What researchers say about exosomes, harm and legitimate trials.
Every feature article on regenmedreview carries a Sources block listing its references. Where the original source material included no external citations, that is stated explicitly rather than left blank.